About
Every life deserves every option.
What we do
Understand the cancer. Connect the evidence. Follow what changes.
OnKommon is a precision-oncology intelligence platform. It helps connect molecular findings, relevant biological and clinical context, treatment-related evidence and the information that changes during the cancer journey — without implying that a digital model makes treatment decisions.
It has exactly two offerings: OnKommon Twin, the longitudinal clinician-led offering, and OnKommon AVATAR, an exploratory solid-tumour research workflow.
OnKommon Twin
Longitudinal precision-oncology intelligence. Four testing pathways, 21 analytical layers, a five-part report and a six-month journey.
OnKommon AVATAR
A biological investigational plan: genomic interpretation with mutation-informed Drosophila modelling and candidate-drug screening.
KPCIRC
Kwatra Precision Cancer Institute & Research Centre — the affiliated clinical partner that convenes the Molecular Tumour Board.
Leadership
Dr. Bharat Kwatra
Research & innovation
Cancer genomics, ctDNA and multi-omic analysis, AI-enabled bioinformatics, trial matching and digital-twin oncology.
Education & memberships
- PhD by Research — Computational Advanced Genomics & AI, Kennedy University, France (doctoral research: The In Silico Patient Avatar)
- MSc Cancer Genomics and Data Sciences, Barts Cancer Institute, Queen Mary University of London
- Summer School: Evolutionary Biology and Genetics, Goethe University, Germany
- Diploma: Medicine, University of Debrecen, Hungary
- Professional Certificate: Precision Oncology Analysis, Harvard University (distance learning)
- Fellow, Royal Society of Medicine · Member, Royal Society of Biology · Member, International Society for Computational Biology · Associate Member, Board of Genetic Counseling, India · Member, The New York Academy of Sciences